^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:trastuzumab rezetecan (SHR-A1811) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

    Excerpt:
    ...advanced non-small cell lung cancer with HER2 expression , amplification, or mutation 4....
    Trial ID:
    NCT04818333
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res
    Title:

    Abstract CT204: Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody-drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study

    Published date:
    04/14/2023
    Excerpt:
    In this single-arm, dose escalation and expansion phase 1 portion, patients with advanced activating HER2-mutant NSCLC...Overall, objective response rate was 40.0% (95% CI 26.4-54.8); median duration of response was 8.3 months (95% CI 5.4-13.7); disease control rate was 86.0% (95% CI 73.3-94.2); median progression-free survival was 10.8 months (95% CI 6.7-15.0)....SHR-A1811 showed tolerable safety profile and durable antitumor activity in heavily pretreated patients with HER2-mutant NSCLC.
    DOI:
    https://doi.org/10.1158/1538-7445.AM2023-CT204